Baxdrostat/dapagliflozin

Phase 3Small molecule

AstraZeneca

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Kidney Disease and HypertensionRecruiting

Chronic Kidney Disease and HypertensionPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Chronic Kidney Disease and Hypertension

NCT07222917

Q1 2028

Phase 3Active, not recruiting

Chronic Kidney Disease and Hypertension

NCT06268873

Q4 2029

Phase 3Recruiting

Chronic Kidney Disease and Hypertension

NCT06742723

Clinical

Trials by Indication[1]

Chronic Kidney Disease and Hypertension3 trials

A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07222917·222 enrolled

A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06742723·5,000 enrolled

A Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06268873·2,554 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Baxdrostat/dapagliflozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Baxdrostat/dapagliflozin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Baxdrostat/dapagliflozin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Baxdrostat/dapagliflozin

Status by Indication[3][1]

Expected Milestones

Q4 2026

Q1 2028

Q4 2029

Trials by Indication[1]

Chronic Kidney Disease and Hypertension3 trials

References

Drug Info

Quick Facts

Related News